News

The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.

Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

A CDC examination of a Delta outbreak in a Texas prison showed unvaccinated persons have higher attack rates, hospitalizations, and deaths, but vaccinated persons can still contract and spread the virus.

A third dose booster vaccination given to persons 60 years of age or over in Israel was confirmed to lower their rate of COVID-19 infection compared to a 2-dose regimen.

New research shows COVID-19 mortality risk to be more nuanced than previous studies.

A presentation of available third-dose data suggest the adverse event rate is consistent with that observed with second doses.

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Patients with cancer now have official confirmation that vaccinating against COVID-19 will protect them from contracting the virus.

With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.

After two doses of the Pfizer-BioNTech COVID-19 vaccine, 83% of allogeneic hematopoietic stem cell transplant recipients showed positive antibody response.

Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.

The regulatory setback is regarding a manufacturing facility concern not associated with the investigative drug, according to the company.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The data, which reflects pre-pandemic routine vaccination levels, showed human papillomavirus vaccine rates increased among teens ages 13-17.

A smaller dosage was used and with their results the two companies plan to submit their data to governmental regulatory agencies around the world.

The Centers for Disease Control and Prevention's (CDC) VISION Network of health care systems provided data for test-negative design analysis of vaccine effectiveness in preventing COVID-19 acute admissions.

After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.

The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.

A new study addressed the clinical outcomes in young adults who were hospitalized with COVID-19 across the United States.

A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.

The emergency authorization granted to combination bamlanivimab and etesevimab is the second indicated in this last year.

A recent study examining trends in time-to-antibiotics among veterans hospitalized with sepsis found that patients received antibiotics faster over time.

Based on recent studies, the company sees benefits in administering booster doses.

Recent data shows that all three COVID-19 vaccines being administered in the United States are showing high rates of vaccine effectiveness (VE).

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

Higher HIV viral loads and additional heart disease factors increase the risk as well.

Johnson & Johnson’s vaccine regimen induced neutralizing antibody responses in 98% of participants 21 days after the second dose.

In a recent speech, Pfizer’s CFO says it might be a matter of weeks for submitting an application for children 6 months to 5 years old.